Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506125 | 1.00 | HTR4 (0.54) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL506123 | 1.00 | HTR4 (0.54) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL505861 | 0.97 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL505862 | 0.97 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL505860 | 0.97 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL8828860 | 0.89 | HTR4 (0.57) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL8828862 | 0.89 | HTR4 (0.57) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL8828865 | 0.89 | HTR4 (0.57) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL9476014 | 0.87 | HTR4 (0.68) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL9476025 | 0.87 | HTR4 (0.68) | HTR4HTR3AHTR1AADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8063070-B2 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-11-22 | — | — | US | disclosed |
| US-7790750-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A | 2007-02-15 | — | — | US | disclosed |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2004-03-25 | — | — | US | disclosed |
| US-6635643-B2 | For treating conditions which are related to impairment of gastric emptying | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-10-21 | — | — | US | disclosed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | disclosed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | disclosed |
| EP-0991410-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999002156-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | HTR4 248/4885HTR3A 555/4885HTR1A 136/4885 |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | HTR4 244/4885HTR3A 492/4885HTR1A 118/4885 |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | HRH2, HRH4, GIPR | HTR4 565/4885HTR3A 756/4885HTR1A 380/4885 |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | CBR1, ALK, CBR3 | HTR4 257/4885HTR3A 664/4885HTR1A 353/4885 |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, SLC10A2, HRH4 | HTR4 389/4885HTR3A 1279/4885HTR1A 1566/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | HTR4 407/4885HTR3A 1036/4885HTR1A 1232/4885 |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | ALK, HRH2, CBR1 | HTR4 149/4885HTR3A 592/4885HTR1A 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.